These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8227490)

  • 41. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.
    Goddard AW; Woods SW; Sholomskas DE; Goodman WK; Charney DS; Heninger GR
    Psychiatry Res; 1993 Aug; 48(2):119-33. PubMed ID: 8416022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder.
    Pollack MH; Rapaport MH; Fayyad R; Otto MW; Nierenberg AA; Clary CM
    J Psychiatr Res; 2002; 36(4):229-36. PubMed ID: 12191627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data.
    Wylie ME; Miller MD; Shear MK; Little JT; Mulsant BH; Pollock BG; Reynolds CF
    J Geriatr Psychiatry Neurol; 2000; 13(1):43-8. PubMed ID: 10753007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.
    Ballenger JC; Wheadon DE; Steiner M; Bushnell W; Gergel IP
    Am J Psychiatry; 1998 Jan; 155(1):36-42. PubMed ID: 9433336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.
    Zwanzger P; Eser D; Nothdurfter C; Baghai TC; Möller HJ; Padberg F; Rupprecht R
    Pharmacopsychiatry; 2009 Nov; 42(6):266-9. PubMed ID: 19924586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apathy and indifference in patients on fluvoxamine and fluoxetine.
    Hoehn-Saric R; Lipsey JR; McLeod DR
    J Clin Psychopharmacol; 1990 Oct; 10(5):343-5. PubMed ID: 2124218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of low-dose intranasal midazolam to treat panic disorder: a pilot study.
    Schweizer E; Clary C; Dever AI; Mandos LA
    J Clin Psychiatry; 1992 Jan; 53(1):19-22. PubMed ID: 1737735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.
    van Vliet IM; den Boer JA; Westenberg HG; Slaap BR
    J Clin Psychopharmacol; 1996 Aug; 16(4):299-306. PubMed ID: 8835705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.
    Black DW; Wesner R; Bowers W; Gabel J
    Arch Gen Psychiatry; 1993 Jan; 50(1):44-50. PubMed ID: 8422221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.
    Bakker A; van Dyck R; Spinhoven P; van Balkom AJ
    J Clin Psychiatry; 1999 Dec; 60(12):831-8. PubMed ID: 10665629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.
    Hirschmann S; Dannon PN; Iancu I; Dolberg OT; Zohar J; Grunhaus L
    J Clin Psychopharmacol; 2000 Oct; 20(5):556-9. PubMed ID: 11001241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
    Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
    Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose-response characterization of the antipanic effects of imipramine.
    Mavissakalian MR; Perel JM
    Psychopharmacol Bull; 1994; 30(2):171-4. PubMed ID: 7831451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.
    Benjamin J; Levine J; Fux M; Aviv A; Levy D; Belmaker RH
    Am J Psychiatry; 1995 Jul; 152(7):1084-6. PubMed ID: 7793450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
    Stein DJ; Westenberg HG; Yang H; Li D; Barbato LM
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):317-23. PubMed ID: 14604447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Paroxysmal neurological manifestations disclosing panic attacks].
    Petiau C; Hirsch E; Peretti S; Sellal F; Hammouti A; Danion JM; Marescaux C
    Rev Neurol (Paris); 1992; 148(8-9):555-9. PubMed ID: 1362998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
    Den Boer JA; Westenberg HG
    Int Clin Psychopharmacol; 1988 Jan; 3(1):59-74. PubMed ID: 2833543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.